Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019 On 18thNovember 2014
Summary The industry analysis specialist, has released its new report, Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Cytomegalovirus (CMV) Infections Therapeutics market. The report identifies the key trends shaping and driving the global Cytomegalovirus (CMV) Infections Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Cytomegalovirus (CMV) Infections Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts.
You can buy this Report @ http://www.jsbmarketresearch.com/healthcaremedical/r-cytomegalovirus-cmv-infections-pipeline-assessment-and-marketforecasts-135247 Scope - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Cytomegalovirus (CMV) Infections Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes. - Analysis of the current and future competition in the seven key countries Cytomegalovirus (CMV) Infections Therapeutics market. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Cytomegalovirus (CMV) Infections Therapeutics market. - Analysis of key recent licensing and partnership agreements in Cytomegalovirus (CMV) Infections Therapeutics market.
Reasons to buy - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Cytomegalovirus (CMV) Infections Therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Cytomegalovirus (CMV) Infections Therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - Whats the next big thing in the global Cytomegalovirus (CMV) Infections Therapeutics market landscape? Identify, understand and capitalize.
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Other industries we cover: • • • • • • • • •
Advertising and Media Automotive and Parts Consumer Goods Healthcare and Medical Finance and Banking Food and Beverages Travel and Tourism Textiles and Clothing SWOT Analysis
Discounts on Market Research Reports till 31st December, 2014 For more inquiries, contact at +91 - 998 729 5242 / contact@jsbmarketresearch.com Table of Content 2 Introduction 2.1 Catalyst 3 Disease Overview 3.1 Etiology and Pathophysiology 3.1.1 Etiology 3.1.2 Pathophysiology 3.1.3 Risk Factors 3.2 Epidemiology 3.2.1 CMV Prevalence in General Population 3.2.2 CMV Prevalence in At-Risk Populations 3.3 Symptoms 3.4 Diagnosis and Referral 3.4.1 CMV DNA PCR 3.4.2 Conventional viral cultures of tissue biopsy or bodily fluids 3.4.3 Shell vial culture 3.4.4 CMV serology 3.4.5 Histopathologic exam with in-situ hybridization 3.4.6 Retinal examination using an indirect ophthalmoscope 3.4.7 PP65 antigenemia test 3.4.8 Referral Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
3.5 Treatment Guidelines 3.6 Disease Management 4 Competitive Assessment 4.1 Overview 4.2 Strategic Competitor Assessment 4.3 Product Profiles for the Major Marketed Products 4.3.1 Ganciclovir sodium 4.3.2 Valcyte (valganciclovir) 4.3.3 CMV-IGIV 4.3.4 Cidofovir 4.3.5 Foscarnet 4.3.6 Summary of Marketed Drugs 5 Opportunity and Unmet Need 5.1 Overview 5.2 Unmet Needs 5.2.1 Unmet Need: Safety 5.2.2 Unmet Need: Efficacy 5.2.3 Unmet Need: Prophylactic Vaccine 5.2.4 Unmet Need: Therapeutic Vaccine 5.2.5 Unmet Need: Patient Compliance 5.2.6 Unmet Need: Patient Awareness 5.2.7 Unmet Need: Physician Education 5.2.8 Unmet Need: Early Diagnosis of CMV in Pregnant Women and Transplant Patients 5.2.9 Unmet Need: Drug Resistance with Currently Available Antiviral Drugs 5.3 Opportunities 5.3.1 Opportunity: Vaccine Development Remains a Major Opportunity 5.3.2 Opportunity: Addressing Patient Compliance for Long-Term Therapy 5.3.3 Opportunity: Generating Physician and Patient Awareness 6 Pipeline Assessment 6.1 Overview 6.2 Strategic Pipeline Assessment 6.3 Pipeline Analysis by Phase of Development 6.3.1 Phase III Clinical Pipeline 6.3.2 Phase II Clinical Pipeline 6.3.3 Phase I Pipeline 6.3.4 Pre-clinical Pipeline 6.3.5 Discovery Pipeline 6.4 Pipeline by Mechanism of Action 6.5 Technology Trends Analytical Framework Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
6.6 Most Promising Drugs in Clinical Development 6.7 Most Promising Drug Profiles 6.7.1 TransVax 6.7.2 AIC246 6.7.3 Maribavir 6.7.4 CMX001 7 Clinical Trial Mapping 7.1 Clinical Trials by Region/Country (US, 5EU and Japan) 7.2 Clinical Trials by Phase 7.3 Clinical Trials by Trial Status 7.4 Clinical Trials by Prominent Sponsors 8 Current and Future Players 8.1 Trends in Corporate Strategy 8.2 Company Profiles 8.2.1 F. Hoffmann-La Roche (Roche) 8.2.2 Vical 8.2.3 AiCuris 8.2.4 ViroPharma 8.2.5 Chimerix 9 Licensing and Partnership Deals 9.1 Overview 9.2 Key Deals and Alliances in the Past 18 Months 10 Market Outlook 10.1 Seven Major Markets Overview 10.2 Regional Analysis 10.2.1 US 10.2.2 France 10.2.3 Germany 10.2.4 Italy 10.2.5 Spain 10.2.6 UK 10.2.7 Japan 10.3 Key Events 10.4 Drivers and Barriers 10.4.1 Drivers for the CMV Infections Market 10.4.2 Barriers for the CMV Infections Market 11 Appendix 11.1 Bibliography 11.2 Abbreviations Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
11.3 Methodology 11.3.1 Coverage 11.3.2 Secondary Research 11.3.3 Forecasting Methodology 11.3.4 Primary Research 11.3.5 Expert Panel Validation 11.4 Physicians and Specialists Included in this Study 11.5 About the Authors 11.5.1 Analysts 11.6 About Us 11.7 Contact Us 11.8 Disclaimer List Of Tables Table 1: Pre-transplant Serologic Status and Relative Risk Table 2: Total Prevalent Cases of CMV Infection in the General Population in the Major Markets (millions), 20112019 Table 3: Total Prevalent Cases in HSCT and SOT Recipients, Infants and HIV Patients with CMV Infection in the Major Markets, 20112019 Table 4: Cytomegalovirus Assay Sensitivities and Predictive Values Table 5: Treatment Guidelines for Cytomegalovirus Table 6: Leading Treatments for Cytomegalovirus Infections, 2012 Table 7: Ganciclovir Sodium SWOT Analysis, 2012 Table 8: Product Profile Valcyte Table 9: Trial Efficacy Details, Valcyte Table 10: Valcyte SWOT Analysis, 2012 Table 11: CMV-IGIV SWOT Analysis, 2012 Table 12: Cidofovir SWOT Analysis, 2012 Table 13: Foscarnet SWOT Analysis, 2012 Table 14: Summary of Marketed Drugs, 2012 Table 15: Overall Unmet Needs Current Level of Attainment (Prophylactic) Table 16: Overall Unmet Needs Current Level of Attainment (Therapeutic) Table 17: Cytomegalovirus Infections Market, Phase III Pipeline, 2012 Table 18: Cytomegalovirus Infections Market, Phase II Pipeline, 2012 Table 19: Cytomegalovirus Infections Market, Phase I Pipeline, 2012 Table 20: Cytomegalovirus Infections Market, Pre-clinical Pipeline, 2012 Table 21: Cytomegalovirus Infections Market, Discovery Pipeline, 2012 Table 22: Comparison of Mechanisms of Actions in Development for Cytomegalovirus Infection, Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
2012 Table 23: Cytomegalovirus Infections Market, Global, Most Promising Drugs in Clinical Development, 2012 Table 24: Product Profile TransVax Table 25: TransVax SWOT Analysis, 2012 Table 26: AIC246 SWOT Analysis, 2012 Table 27: Maribavir SWOT Analysis, 2012 Table 28: CMX001 SWOT Analysis, 2012 Table 29: Cytomegalovirus Infections, Global, Clinical Trials by Phase, 2012 Table 30: Cytomegalovirus Infections, Global, Clinical Trials by Status of Development, 2012 Table 31: Cytomegalovirus Infections, Overall Sponsor Mix, 2012 Table 32: Key Companies in the Cytomegalovirus Infections Market, 2012 Table 33: Roches Cytomegalovirus Infections Portfolio Assessment, 2012 Table 34: Roches Cytomegalovirus Infections Market SWOT Analysis, 2012 Table 35: Vicals Cytomegalovirus Infections Portfolio Assessment, 2012 Table 36: Vicals Cytomegalovirus Infections Market SWOT Analysis, 2012 Table 37: AiCuris Cytomegalovirus Infections Portfolio Assessment, 2012 Table 38: AiCuris Cytomegalovirus Infections Market SWOT Analysis, 2012 Table 39: ViroPharmas Cytomegalovirus Infections Portfolio Assessment, 2012 Table 40: ViroPharmas Cytomegalovirus Infections Market SWOT Analysis, 2012 Table 41: Chimerixs Cytomegalovirus Infections Portfolio Assessment, 2012 Table 42: Chimerixs Cytomegalovirus Infections Market SWOT Analysis, 2012 Table 43: Strategic Deals and Alliances for Cytomegalovirus Infections, 2012 Table 44: Sales Forecasts ($m) for Cytomegalovirus Infections Market in the Seven Major Markets, 20112019 Table 45: Sales Forecasts ($m) for Cytomegalovirus Infections in the United States, 20112019 Table 46: Sales Forecasts ($m) for Cytomegalovirus Infections in France, 20112019 Table 47: Sales Forecasts ($m) for Cytomegalovirus Infections in Germany, 20112019 Table 48: Sales Forecasts ($m) for Cytomegalovirus Infections in Italy, 20112019 Table 49: Sales Forecasts ($m) for Cytomegalovirus Infections in Spain, 20112019 Table 50: Sales Forecasts ($m) for Cytomegalovirus Infections in the UK, 20112019 Table 51: Sales Forecasts ($m) for Cytomegalovirus Infections in Japan, 20112019 Table 52: Key Events Impacting Sales for Cytomegalovirus Infections, 2012 Table 53: Cytomegalovirus Infections Market Drivers and Barriers, 2012 Table 54: Key Launch Dates Table 55: Key Patent Expiries List Of Figures Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Figure 1: Cytomegalovirus Infection in Organ Transplant Patients Figure 2: Referral Pathway for Cytomegalovirus Infection Figure 3: Strategic Competitor Assessment of Marketed Products in Cytomegalovirus Infections (Prophylactic) Market, 2012 Figure 4: Strategic Competitor Assessment of Marketed Products in Cytomegalovirus Infections (Therapeutics) Market, 2012 Figure 5: Opportunity and Unmet Need in the Cytomegalovirus Infections (Prophylactic) Market, 2012 Figure 6: Opportunity and Unmet Need in the Cytomegalovirus Infections (Therapeutic) Market, 2012 Figure 7: Cytomegalovirus Infections Market, Clinical Pipeline by Mechanism of Action (%), 2012 Figure 8: Technology Trends Analytics Framework, 2012 Figure 9: Technology Trends Analytics Framework Unmet Need Gap Analysis, 2012 Figure 10: Cytomegalovirus Infections, Global, Clinical Trials by Country, 2012 Figure 11: Cytomegalovirus Infections Leading Companies Participating in Clinical Trials, 2012 Figure 12: Sales Forecasts ($m) for Cytomegalovirus Prophylactic Market in the Seven Major Markets, 20112019 Figure 13: Sales Forecasts ($m) for Cytomegalovirus Therapeutic Market in the Seven Major Markets, 20112019 Figure 14: Seven Major Market Sales for Cytomegalovirus Prophylactic Market by Region, 20112019 Figure 15: Seven Major Market Sales for Cytomegalovirus Therapeutic Market by Region, 20112019
Report Price: Licence Type
Price
$ 5995
Site Licence
$ 11990
Enterprise Wide Licence
$ 17985
Related Reports: Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Unstable Angina Therapeutics - Pipeline Assessment and Market Forecast to 2018 Venous Thromboembolism (VTE) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Athletes Foot Therapeutics - Pipeline Assessment and Market Forecasts to 2019 HIV-Associated Diarrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Syphilis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Respiratory Syncytial Virus (RSV) Prophylactic - Pipeline Assessment and Market Forecasts to 2019 Vaginitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Clostridium difficile Infection (CDI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
You can order this report by calling on +91 - 998 7295 242 or mail us your contact details at contact@jsbmarketresearch.com About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along with providing in-depth analysis though reports, JSB market research also provides regular updates of the market though newsletters. Our reports are a well-researched work of market researchers with an extensive knowledge and a good level of market experience.
To know more on Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019 http://www.jsbmarketresearch.com/healthcare-medical/r-cytomegaloviruscmv-infections-pipeline-assessment-and-market-forecasts-135247
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/